|
Jan 7
|
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
|
|
Dec 20
|
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
|
|
Dec 19
|
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
|
|
Nov 29
|
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
|
|
Nov 20
|
Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism
|
|
Nov 15
|
Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA
|
|
Nov 8
|
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Ascendis Pharma Reports Third Quarter 2023 Financial Results
|
|
Apr 27
|
Ascendis Pharma Reports First Quarter 2023 Financial Results
|
|
Apr 22
|
An Intrinsic Calculation For Ascendis Pharma A/S (NASDAQ:ASND) Suggests It's 20% Undervalued
|